Premium
Pharmacological treatment of schizophrenia – a review of progress
Author(s) -
Dimitrelis Konstantinos,
Shankar Rohit
Publication year - 2016
Publication title -
progress in neurology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 12
eISSN - 1931-227X
pISSN - 1367-7543
DOI - 10.1002/pnp.430
Subject(s) - schizophrenia (object oriented programming) , holy grail , polypharmacy , psychosis , psychology , psychiatry , neuroscience , medicine , psychotherapist , pharmacology , computer science , world wide web
Since much of our knowledge about the neurobiology of schizophrenia derives from the initial discovery that chlorpromazine was effective in treating psychosis, pharmacological research has mostly concentrated on dopamine‐blocking agents. Here, the authors discuss the situation where there is no single pharmacological agent on the horizon that could serve as the ‘holy grail’ to address the full range of symptoms of schizophrenia and what the immediate future holds with the widespread use of polypharmacy.